Source file signed link, expires in 15 minutes
Extracted text 24
Page 1
PUBLIC EXPOSE LABS 2025
Page 2
TABLE OF CONTENTS 1. Company Profile 2. Financial Overview 3. Business Review 4. 2025 Performance Highlights 5. Business Outlook And Strategy For 2026
Page 3
COMPANY PROFILE
Page 4
PROFIL PERSEROAN INTRODUCTION This presentation has been prepared specifically for the 2025 Public Expose of PT UBC Medical Indonesia Tbk (the “Company”). The information presented herein provides a general overview of the Company’s business performance up to the date of this presentation and is subject to change at any time without prior notice. This presentation may contain forward-looking statements, including projections of future ratios and performance. Actual results may differ materially from those expressed or implied in such forward-looking statements. The Company advises stakeholders to use the information contained herein with due care and discretion.
Page 5
COMPANY PROFILE PT UBC MEDICAL INDONESIA TBK (the "Company") is a Limited Liability Company established on June 9, 2014, and operates as a distributor of medical devices. Until 2025, the Company demonstrated continuous growth, both in terms of operations and product portfolio. The Company actively provides innovative diagnostic solutions, covering various needs such as immunodiagnostics, molecular diagnostics, and other diagnostic systems, to support the improvement of the quality of healthcare services in Indonesia. The Company has also been appointed as a distributor based on Letters of Authorization from its principals, In-Vitro Diagnostic manufacturers from developed countries, including Japan, Germany, Finland, and China, to provide the best technology to laboratories throughout Indonesia. Supported by an extensive distribution network, industry experience, and a commitment to quality standards, the Company continues to strengthen its position as a trusted provider of medical device solutions. Going forward, the Company is committed to continued sustainable growth and making a significant contribution to supporting the national healthcare system.
Page 6
COMPANY PROFILE
Milestone
2015- 2017- 2020-
2014
2016 2018 2021
The Company was established in The Company obtained a Medical The Company was successfully The Company was successfully
collaboration with PT Inodia. Device Distributor License (IPAK) from appointed as a distributor for the appointed as a distributor for the
the Ministry of Health. Ministry of Health's procurement in Ministry of Defense's procurement of
pilot project for cancer screening COVID-19 testing laboratories.
The Company was appointed as services.
distributor for Qiagen and Revvity.
2022 2023 2024 2025
The Company obtained the SNI ISO The Company obtained CDAKB Certification as a On July 10, 2024, the • The Company actively participates in various scientific forums and
9001:2015 Quality Management System Medical Device Distributor. Company officially became national health congresses, including KONAS XII, PIT XXIV PDSPATKLIN 2025,
Certification. a public company under New-born Screening Campaign Day 2025, 13th PIT IKA, and Respina 2025,
The Company established a subsidiary, PT Esora the ticker code LABS. as part of its commitment to supporting diagnostic innovation and
The Company is a distributor of new-born Medika Indonesia. healthcare professional education.
supplies to seven vertical hospital
laboratories under the Ministry of Health. The Company supplied medical devices for HPV • The Company continues to expand its portfolio of diagnostic products
(cervical cancer) screening programs and for TB and healthcare solutions, including IGRA solutions for TB, molecular
The Company also serves as a distributor screening programs aimed at achieving a TB- diagnostic systems, retinal disease screening services, and other
of medical devices for new-born free Indonesia by 2030. innovations.
screening to the Directorate as part of the
SHK (Congenital Hypothyroidism The Company also successfully transferred • The Company participated in supporting primary core health services for
Screening) program. technology and produced molecular diagnostic the elderly who have mobility disabilities and chronic diseases such as
products, which are among the most complex in diabetes.
the diagnostic industry.
Page 7
BOARD OF DIRECTORS & BOARD OF COMMISSIONERS F.X YOSHUA RAINTJUNG MARCELLA ANGELIN NATHAN TIRTANA SUYANTO President Director Director President Commissioner Independent Commissioner
Page 8
FINANCIAL HIGHLIGHT
Page 9
IKHTISAR KEUANGAN ASSETS: ❖ Total assets: Rp228,187 million (+12% YoY) ❖ Cash: Rp41,165 million ❖ Accounts receivable: Rp32,928 million ❖ Inventory: Rp76,596 million Liabilities: ❖ Total liabilities: IDR 75,723 million (vs. IDR 64,844 million in 2024) ❖ Current liabilities: IDR 72,268 million ❖ Long-term liabilities: IDR 3,455 million EQUITY ❖ Total equity: Rp152,463 million (vs. Rp138,754 million in 2024) ❖ Paid-in capital (net): ~Rp133 million ❖ Retained earnings: Rp18,728 million PROFIT AND LOSS ❖ Revenue: Rp199,295 million ❖ Gross profit: Rp79,717 million ❖ Operating profit: Rp21,481 million ❖ Profit for the year: Rp13,507 million ❖ Profit growth: +357% YoY
Page 10
BUSINESS REVIEW
Page 11
COMPANY POSITION
DIAGNOSTIC INDUSTRION
Chemistry Hematology Immunology Molecular Next Gen. Sequencing
• Large Volume • Medium Volume • Small Volume
• Low Price per Test • Medium Price per Test • Price per Test very
• Product-Based in • Medium Technology high
the Diagnostic • Many Competitors • High Technology
Industry • Few Competitors
• Many Competitors • Large Volume • Large Volume
• Low Price per Test • High Price per Test
• Low Technology • High Technology
• Many Competitors • Few Competitors
Page 12
COMPANY PRODUCT I
In the diagnostic medical device industry, the molecular category utilizes advanced technology. The products distributed by the Company include in-vitro
diagnostic medical devices (instruments) and consumables/reagents, specializing in the detection of infectious diseases and congenital disorders that fall
within the molecular category.
Consumables: Disposable medical
devices used in the process of
Instrumen: Equipment, machines, treatment or health examinations.
and analyzers in the laboratory
that function to process biological
specimens or samples, as well as Reagent: Chemical agents used in
to measure and examine the laboratory tests to detect, measure,
levels or contents of specific examine, and produce other
substances. substances.
Direct Operational Tender /
Sales Collaboration Procurement
Through a purchase order or Through collaboration with private and government Participating in tenders or selection
contract with a specified term. laboratories, the Company places or loans laboratory processes as part of projects primarily
instruments on the condition that the laboratories are conducted by the government.
required to use reagents supplied by the Company.
Page 13
The Company provides products for the diagnosis of tuberculosis (TB), including both drug-susceptible and drug-resistant types.
COMPANY PRODUCT II
LTBI Management InaTB & ID Care HPV DNA Test InaHPV New-born Screening
The Company provides products The Company provides WHO- New-born screening products
for diagnosing tuberculosis (TB), recommended products, namely used to determine whether a
including both drug-sensitive TB the HPV DNA Test using molecular baby is at high risk of congenital
and drug-resistant TB, covering methods to detect the HPV virus disorders or developmental
the detection of MTB bacteria as that causes cervical cancer. problems.
well as drug resistance genes
Page 14
COMPANY PRODUCT III
Infectious Disease
The Company provides tools for
syndromic panel testing of
patient samples, which are used
to analyze infectious disease
profiles in the respiratory,
digestive, and central nervous
systems.
Liver Fibrosis Detection
The Company is also
currently active in the non-
IVD sector, providing
elastography devices for the
All in One GP Workstation detection of liver fibrosis and
steatosis.
A health screening tool capable of
detecting up to 13 medical indicators,
including blood sugar, lipids, hemoglobin,
blood pressure, urine, and more, equipped
with Artificial Intelligence (AI).
Page 15
Marketing and Distribution Network
The Company’s distribution network covers 19 regions across Indonesia, focusing on major cities and
highly populated areas.
Distribution Areas include:
Aceh, North Sumatra, West Sumatra, South
Sumatra, Lampung, Banten, Jabodetabek, West
Java, Central Java, East Java, Yogyakarta, Bali,
Nusa Tenggara, West Kalimantan, East
Kalimantan, South Kalimantan, North Sulawesi,
South Sulawesi, Papua
Marketing activities target both private sector
and government customers.
Private sector customers include Hospitals,
Clinical Laboratories & Diagnostic Centers.
Total B2B Customers Government customers include Central
(FY 2025):
➢ Hospitals: 76
Government Hospitals, Regional Public
➢ Institutions: 27 Hospitals, Ministry of Health & Ministry of
➢ Laboratories: 26 Defense.
➢ Community Health
Centers: 7
➢ Universities: 3
➢ Other Institutions: 33
Page 16
Competitive Rp
Advantages Partnership with
reputable and
leading principals
Reliable after-sales
support
Extensive
distribution coverage
Page 17
2025 PERFORMANCE HIGHLIGHTS
Page 18
Commercial Highlight 2025 Sales increase from IDR 147 billion in 2024 to IDR 199 billion in 2025, representing a year-on-year (YoY) growth of around 35%. Strengthened product portfolio through a strategic partnership with Hisky Medical for elastography-based liver disease diagnostic technology, marking the early adoption of non-invasive diagnostic technology in Indonesia. Expansion of strategic partnerships through collaboration on Garea products, supporting national healthcare programs for populations with limited mobility via networks of community health centers (Puskesmas), general practitioners, and independent midwives. Market leader in Syndromic Testing using POCT PCR Qiastat.
Page 19
Commercial Highlight 2025 Throughout 2025, PT UBC Medical Indonesia Tbk successfully recorded solid commercial performance, with growth driven by strengthening its core business, diversifying its product portfolio, and developing strategic partnerships with various healthcare stakeholders. The Company continues to capitalize on growth opportunities in the medical diagnostics sector through a commercial approach focused on high-value healthcare technology solutions. The Company's product lines, including Newborn Screening, Tuberculosis (TB), Human Papillomavirus (HPV), and several other flagship products, recorded very significant growth throughout 2025. This increase was driven by the increasingly widespread implementation of newborn screening programs in various healthcare facilities in Indonesia and growing awareness of the importance of early detection of congenital diseases in infants. In addition to strengthening its core business, the Company is also expanding its portfolio through a strategic collaboration with Hisky Medical to introduce elastography-based liver disease diagnostic technology in Indonesia. Through this collaboration, the Company was appointed as the exclusive distributor of liver fibrosis diagnostic devices, with initial installations already underway at Medistra Hospital in Jakarta. This initiative strengthens the Company's position as a trusted partner for healthcare facilities in providing modern diagnostic technology that enables faster and more accurate disease detection.
Page 20
Financial Highlight 2025 📊 Key Financial Performance Throughout 2025, the Company recorded very solid financial performance with significant growth across all key indicators. Revenue increased to approximately Rp 199.3 billion, growing by approximately 35% year-on-year, driven by increased demand and effective distribution network expansion. In line with this growth, the Company significantly increased net profit to Rp 13.5 billion, a jump of more than 350% compared to the previous year, reflecting the success of its market penetration strategy, business strategy, operational, and efficiency. 📈 Profitability & Efficiency The Company also recorded strong profitability improvement, with gross profit reaching IDR 79.7 billion, marking a substantial increase from the prior year. This demonstrates the Company’s ability to maintain healthy margins while improving efficiency in cost of revenue. The faster growth in profit relative to revenue confirms the emergence of operating leverage, creating opportunities for further margin expansion in the future. 🏗️ Healthy Financial Structure From a balance sheet perspective, total assets increased to approximately IDR 228 billion, reflecting continued business expansion. Equity grew to around IDR 152.5 billion, supported by strong accumulated net earnings, thereby strengthening the Company’s capital structure. Meanwhile, liabilities increased moderately to IDR 75 billion, remaining at a well-managed level to support business growth. 💰 Cash Flow & Liquidity The Company recorded positive operating cash flow of IDR 22.9 billion, demonstrating the business’s ability to generate cash sustainably. This reflects strong earnings quality as well as effective working capital management.
Page 21
BUSINESS OUTLOOK AND STRATEGY FOR 2026
Page 22
COMPANY STRATEGY FOR 2026
Entering 2026, the Company sees that the medical device industry in Indonesia still holds
strong growth potential, driven by increasing demand for healthcare services, the
strengthening of the national health system, and growing public awareness of high-quality
diagnostic services.
Strengthening Product Portfolio
and Technological Innovation
Expansion of the National Exploration and Penetration
Through partnerships with global Distribution Network in 2026 of New Segments
principals and the development of
high value-added products, the In 2026, the Company plans to The Company will explore and
Company will continue to expand its distribution network develop new market segments
enhance its product portfolio. The across various strategic regions with high growth potential, in line
primary focus will be on in Indonesia, particularly in cities with the evolving dynamics of
laboratory diagnostic products, experiencing significant growth healthcare service needs.
hospital medical devices, and in healthcare facilities.
medical technologies that support These penetration efforts will be
the efficiency of healthcare The strengthening of the supported by service innovation,
services. distribution network will also be strengthened marketing
supported by increased logistics capabilities, and strategic
In addition, the Company will capacity and a more integrated collaborations to expand market
optimize the use of technology supply chain management reach and enhance the
and digitalization in its distribution system. Company’s contribution to
systems and after-sales services sustainable growth.
to improve the quality of service
delivered to customers.
Page 23
Providing aid
to victims of
natural
disasters in
North
Sumatra in
the form of
medicines
and medical
equipment.
Fundraising for meningitis patients
to participate in commemorating
World Meningitis Day
CSR
ACTIVITIES
Distribution of donations of 10 isets of GP Workstations
to remote health centers in Aceh Province.
Page 24
Thank You
For Your Attention
United Because We Care
Learn More
www.ubcindonesia.com
Names mentioned 9 people and organisations named in the text · linked when the evidence is strong
unresolved
org
Ministry of Health.
p.6 ×2
unresolved
org
Ministry of Health's
p.6
unresolved
org
Ministry of Defense's
p.6
unresolved
org
PT Esora
p.6
unresolved
org
Ministry of Health & Ministry
p.15
Extraction attempts how the parser did, and what it refused
Nothing structured was extracted from this document — the attempts below say why.
No extraction attempted yet.